Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3010634 | 1.00 | P2RX7 (0.57) | P2RX7EPHX2AAK1ALDH1A1KMT2A | |
| SCHEMBL2995319 | 0.90 | P2RX7 (0.55) | P2RX7EPHX2ALDH1A1KMT2ACCR8 | |
| SCHEMBL8233898 | 0.90 | P2RX7 (0.47) | P2RX7ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL13243922 | 0.88 | P2RX7 (0.63) | P2RX7EPHX2AAK1ALDH1A1KMT2A | |
| SCHEMBL3004039 | 0.88 | P2RX7 (0.63) | P2RX7EPHX2AAK1ALDH1A1KMT2A | |
| SCHEMBL13243937 | 0.87 | P2RX7 (0.58) | P2RX7EPHX2AAK1ALDH1A1KMT2A | |
| SCHEMBL13243931 | 0.87 | P2RX7 (0.58) | P2RX7EPHX2AAK1ALDH1A1KMT2A | |
| SCHEMBL3005209 | 0.86 | P2RX7 (0.64) | P2RX7EPHX2ALDH1A1KMT2ANPC1 | |
| SCHEMBL3007428 | 0.86 | P2RX7 (0.64) | P2RX7EPHX2ALDH1A1KMT2ANPC1 | |
| SCHEMBL2999020 | 0.86 | P2RX7 (0.64) | P2RX7EPHX2ALDH1A1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2007109201-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885EPHX2 569/4885AAK1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.